Skip to search boxSkip to navigationSkip to main content

B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality

  • Rachelle G. Veenstra
    ,
  • Ryan Flynn
    ,
  • Katharina Kreymborg
    ,
  • Cameron McDonald-Hyman
    ,
  • Asim Saha
    ,
  • Patricia A. Taylor
*Corresponding author for this work
  • University of Minnesota Twin Cities
    ,
  • Memorial Sloan-Kettering Cancer Center
    ,
  • University of Freiburg
    ,
  • University of California at Davis
    ,
  • University of North Carolina at Chapel Hill
    ,
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Abstract

Members of the B7 family have been shown to be important for regulating immune responses by providing either positive or negative costimulatory signals. The function of B7-H3 has been controversial. We show that B7-H3 is upregulated in graft-versus-host disease (GVHD) target organs, including the colon, liver, and lung. Infusion of allogeneic donor T cells into B7-H32/2 vs wild-type (WT) recipients resulted in increased GVHD lethality associated with increased T-cell proliferation, colonic inflammatory cytokines, and destruction of epithelial barriers. Allogeneic B7-H32/2 vs WT donor T cells also had increased T-cell proliferation and GVHD lethality associated with increased proliferation and cytokine secretion in the spleen, intraepithelial lymphocyte inflammatory cytokines, and intestinal permeability. Both resting and activated regulatory T cells (Tregs) lack B7-H3 messenger RNA. Consistent with these data, GVHD was augmented in recipients of B7-H32/2 Treg-depleted grafts. In two delayed lymphocyte infusion (DLI) models, T cells lacking B7-H3 are capable of providing graft-versus-leukemia (GVL) effects. We conclude that B7-H3 is responsible for providing a negative costimulatory signal. Our studies provide support for developing and testing new therapies directed toward the B7-H3 pathway, including approaches to augment host B7-H3 early after bone marrow transplantation to prevent GVHD and to develop potent antagonistic antibodies later after transplant to facilitate DLI-mediated GVL without GVHD complications.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 3335-3346 (12 pages)

Journal (Volume, Issue Number)

Blood (Volume 125, Issue 21)

Publication milestones

  • Published - 2015

Publication status

Published - 2015

ISSN

0006-4971

Publication IDs

  • Scopus: 84979860701
  • PubMed: 25814530
  • ORCID: /0000-0002-7711-2858/work/58011224

Publication metrics

Metrics

Scopus
citations
SciVal
FWCI
1.44
SciVal
Author count
19
SciVal
citations
37
SciVal
Paper percentile
92
SciVal
Top percentile
10
Fractional count
1
Fractional count
0.05
Fractional count
18
Fractional count
0.95
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Captures
77
Social media
1
Citation count
68

Funding Details

This work was supported in part by National Institutes of Health grants R01 HL56067 from the National Heart, Lung, and Blood Institute, and R01 AI 34495, P01 AI 056299, and T32 AI 007313 from the National Institute of Allergy and Infectious Diseases.
FundersFunding numbers
NIH
R01 HL56067
NHLBI
R01HL118979, P01 AI 056299, T32 AI 007313, R01 AI 34495
NIAID
-